BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19090007)

  • 1. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha.
    Tandle A; Hanna E; Lorang D; Hajitou A; Moya CA; Pasqualini R; Arap W; Adem A; Starker E; Hewitt S; Libutti SK
    Cancer; 2009 Jan; 115(1):128-39. PubMed ID: 19090007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity.
    Yuan Z; Syrkin G; Adem A; Geha R; Pastoriza J; Vrikshajanani C; Smith T; Quinn TJ; Alemu G; Cho H; Barrett CJ; Arap W; Pasqualini R; Libutti SK
    Cancer Gene Ther; 2013 Jan; 20(1):46-56. PubMed ID: 23154431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies.
    Staquicini FI; Smith TL; Tang FHF; Gelovani JG; Giordano RJ; Libutti SK; Sidman RL; Cavenee WK; Arap W; Pasqualini R
    Cancer Gene Ther; 2020 May; 27(5):301-310. PubMed ID: 31130731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of radiation and systemic, RGD-targeted, adeno-associated virus phage-TNF gene therapy in a mouse model of spontaneously metastatic melanoma.
    Quinn TJ; Healy N; Sara A; Maggi E; Claros CS; Kabarriti R; Scandiuzzi L; Liu L; Gorecka J; Adem A; Basu I; Yuan Z; Guha C
    Cancer Gene Ther; 2017 Jan; 24(1):13-19. PubMed ID: 27934883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector.
    Hajitou A
    Adv Genet; 2010; 69():65-82. PubMed ID: 20807602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
    Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
    Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas.
    Smith TL; Yuan Z; Cardó-Vila M; Sanchez Claros C; Adem A; Cui MH; Branch CA; Gelovani JG; Libutti SK; Sidman RL; Pasqualini R; Arap W
    Proc Natl Acad Sci U S A; 2016 Mar; 113(9):2466-71. PubMed ID: 26884209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin Improves Cancer Cell Targeting by Filamentous Phage Gene Delivery Vectors.
    Tsafa E; Bentayebi K; Topanurak S; Yata T; Przystal J; Fongmoon D; Hajji N; Waramit S; Suwan K; Hajitou A
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction.
    Tsafa E; Al-Bahrani M; Bentayebi K; Przystal J; Suwan K; Hajitou A
    Oncotarget; 2016 Aug; 7(32):52135-52149. PubMed ID: 27437775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer.
    Suwan K; Yata T; Waramit S; Przystal JM; Stoneham CA; Bentayebi K; Asavarut P; Chongchai A; Pothachareon P; Lee KY; Topanurak S; Smith TL; Gelovani JG; Sidman RL; Pasqualini R; Arap W; Hajitou A
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18571-18577. PubMed ID: 31375630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and construction of targeted AAVP vectors for mammalian cell transduction.
    Hajitou A; Rangel R; Trepel M; Soghomonyan S; Gelovani JG; Alauddin MM; Pasqualini R; Arap W
    Nat Protoc; 2007; 2(3):523-31. PubMed ID: 17406616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An AAVP-based solid-phase transducing matrix for transgene delivery: potential for translational applications.
    Smith TL; Souza GR; Sidman RL; Arap W; Pasqualini R
    Cancer Gene Ther; 2017 Aug; 24(8):358-360. PubMed ID: 28548103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors.
    Yata T; Lee EL; Suwan K; Syed N; Asavarut P; Hajitou A
    Mol Cancer; 2015 Jun; 14():110. PubMed ID: 26037383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.
    Przystal JM; Umukoro E; Stoneham CA; Yata T; O'Neill K; Syed N; Hajitou A
    Mol Oncol; 2013 Feb; 7(1):55-66. PubMed ID: 22951279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of histone deacetylation and DNA methylation improves gene expression mediated by the adeno-associated virus/phage in cancer cells.
    Kia A; Yata T; Hajji N; Hajitou A
    Viruses; 2013 Oct; 5(10):2561-72. PubMed ID: 24153059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Inhibition of Histone Deacetylation in Melanoma Increases Targeted Gene Delivery by a Bacteriophage Viral Vector.
    Campbell S; Suwan K; Waramit S; Aboagye EO; Hajitou A
    Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29690504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity.
    Kianmanesh A; Hackett NR; Lee JM; Kikuchi T; Korst RJ; Crystal RG
    Hum Gene Ther; 2001 Nov; 12(17):2035-49. PubMed ID: 11747595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin.
    Menon C; Ghartey A; Canter R; Feldman M; Fraker DL
    Ann Surg; 2006 Nov; 244(5):781-91. PubMed ID: 17060772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors.
    Dondossola E; Dobroff AS; Marchiò S; Cardó-Vila M; Hosoya H; Libutti SK; Corti A; Sidman RL; Arap W; Pasqualini R
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2223-8. PubMed ID: 26858439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
    Liu Y; Zhang W; Cheung LH; Niu T; Wu Q; Li C; Van Pelt CS; Rosenblum MG
    Neoplasia; 2006 May; 8(5):384-93. PubMed ID: 16790087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.